

AMENDMENT IN SUPPORT OF RCE
Appl. No. 09/615,872

IN THE CLAIMS:

The following listing of claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

Claim 1 (currently amended) A composition comprising a monoclonal antibody wherein the monoclonal antibody is produced by the KKO hybridoma cell line deposited under ATCC No.: PTA-6133 ~~which is capable of binding specifically with a platelet factor 4 (PF4)/heparin complex, wherein said antibody preferentially binds with said PF4/heparin complex relative to said binding with either PF4 or heparin alone.~~

Claim 2 (currently amended) The composition of claim 1, wherein said the monoclonal antibody is capable of binding specifically with a PF4/glycosaminoglycan complex, wherein said glycosaminoglycan is not heparin platelet factor 4 (PF4)/heparin complex, wherein the monoclonal antibody preferentially binds with the PF4/heparin complex relative to a binding with either PF4 or heparin alone.

Claim 3 (currently amended) The composition of claim 1, wherein said the monoclonal antibody is capable of activating activates platelets ~~with PF4 and heparin present through a PF4/heparin dependent mechanism.~~

AMENDMENT IN SUPPORT OF RCE
Appln. No. 09/615,872

Claim 4 (cancelled)

Claim 5 (currently amended) The composition of claim 1, wherein ~~is said the monoclonal~~ antibody is a murine monoclonal antibody ~~which comprises a heavy chain polypeptide of SEQ ID NO:1 and a light chain polypeptide of SEQ ID NO:2.~~

Claim 6 (currently amended) The composition of claim 1, wherein ~~said the monoclonal~~ antibody is a humanized antibody.

Claims 7-11 (cancelled)

Claim 12 (currently amended) A method of making a humanized monoclonal antibody ~~which is capable of binding specifically with a platelet factor 4 (PF4)/heparin complex, wherein said antibody preferentially binds with said PF4/heparin complex relative to said binding of said antibody with either PF4 or heparin alone, said the method comprising:~~

~~a) obtaining a monoclonal antibody which is capable of binding specifically with a PF4/heparin complex, wherein said antibody preferentially binds with said PF4/heparin complex relative to said binding of said antibody with either PF4 or heparin alone,~~

Date: August 27, 2004

Page 3 of 15

RA&M Ref. No.:
2687-021/MC-166

AMENDMENT IN SUPPORT OF RCE
Appln. No. 09/615,872

selected from the group consisting of:

a KKO monoclonal antibody produced by the hybridoma
cell line deposited under ATCC No. PTA-6133; and
an antibody which can compete with the monoclonal
antibody produced by the hybridoma cell line deposited
under ATCC No.: PTA-6133;

~~b) humanizing said the monoclonal antibody obtained in a~~
7 whereby a humanized monoclonal antibody is made.

Claim 13 (currently amended) The method of claim 12, wherein
~~said the monoclonal antibody obtained in a) comprises a heavy~~
~~chain polypeptide having an amino acid sequence which shares at~~
~~least about 80% sequence identity with SEQ ID NO:1 and a light~~
~~chain polypeptide having an amino acid sequence which shares at~~
~~least about 80% sequence identify with SEQ ID. NO:3~~
preferentially binds to human Platelet Factor 4 (PF4)/heparin
complex relative to a binding of the monoclonal antibody obtained
in a) with either PF4 or heparin alone.

Claim 14. (currently amended) The method of claim 12, wherein
the ~~said~~ monoclonal antibody obtained in a) is a murine
monoclonal antibody ~~(KKO) which comprises a heavy chain~~
~~polypeptide of SEQ ID NO: 1 and a light chain polypeptide of SEQ~~
~~ID NO:2.~~

AMENDMENT IN SUPPORT OF RCE**Appln. No. 09/615,872**

Claims 15-41. (cancelled)

Claim 42. (new) A hybridoma cell line deposited as ATCC No.: PTA-6133.

Claim 43. (new) A monoclonal antibody produced by a hybridoma cell line deposited as ATCC No.: PTA-6133.

Claim 44. (new) A monoclonal antibody which binds to a PF4/heparin complex, wherein the monoclonal antibody has an epitopic specificity of the monoclonal antibody produced by a hybridoma cell line deposited as ATCC No.: PTA-6133.

Claim 45. (new) The monoclonal antibody of claim 44 wherein the monoclonal antibody activates platelets through a PF4/heparin dependent mechanism.

Claim 46. (new) A monoclonal antibody that binds to a PF4/heparin complex, wherein the monoclonal antibody is selected from the group consisting of:

A monoclonal antibody produced by a hybridoma cell line deposited under ATCC No. PTA-6133; and
an antibody which can compete with the monoclonal antibody produced by the hybridoma cell line deposited under ATCC

AMENDMENT IN SUPPORT OF RCE**Appln. No. 09/615,872****No.: PTA-6133 for a binding to a PF4/heparin complex.**